Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions

References

• Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155:1022–1033 e10. doi:10.1053/j.gastro.2018.07.009
   PubMed Web of Science ®Google Scholar
• Mougey EB, Nguyen V, Gutierrez-Junquera C, et al. STAT6 variants associate with relapse of eosinophilic esophagitis in patients receiving long-term proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2020;19:2046–2053.e2. doi:10.1016/j.cgh.2020.08.020
   PubMed Web of Science ®Google Scholar
• Mougey EB, Williams A, Coyne AJK, et al. CYP2C19 and STAT6 variants influence the outcome of proton pump inhibitor therapy in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2019;69:581–587. doi:10.1097/MPG.0000000000002480
   PubMed Web of Science ®Google Scholar
• Furuta GT, Katzka DA. Eosinophilic esophagitis. N Engl J Med. 2015;373:1640–1648. doi:10.1056/NEJMra1502863
   PubMed Web of Science ®Google Scholar
• Navarro P, Arias A, Arias-Gonzalez L, et al. Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2019;49:1116–1125. doi:10.1111/apt.15231
   PubMed Web of Science ®Google Scholar
• O’Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of Eosinophilic Esophagitis. Gastroenterology. 2018;154:333–345. doi:10.1053/j.gastro.2017.06.065
   PubMed Web of Science ®Google Scholar
• Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020;158:1776–1786. doi:10.1053/j.gastro.2020.02.038
   PubMed Web of Science ®Google Scholar
• Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133:1342–1363. doi:10.1053/j.gastro.2007.08.017
   PubMed Web of Science ®Google Scholar
• Muir AB, Merves J, Liacouras CA. Role of endoscopy in diagnosis and management of pediatric eosinophilic esophagitis. Gastrointest Endosc Clin N Am. 2016;26:187–200. doi:10.1016/j.giec.2015.08.006
   PubMedGoogle Scholar
• Friedlander JA, Fleischer DM, Black JO, et al. Unsedated transnasal esophagoscopy with virtual reality distraction enables earlier monitoring of dietary therapy in eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2021;9:3494–3496. doi:10.1016/j.jaip.2021.06.030
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145:1230–6 e1-2. doi:10.1053/j.gastro.2013.08.015
   PubMed Web of Science ®Google Scholar
• Dellon ES, Kim HP, Sperry SL, et al. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc. 2014;79:577–85 e4. doi:10.1016/j.gie.2013.10.027
   PubMed Web of Science ®Google Scholar
• Attwood SE, Smyrk TC, Demeester TR, et al. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci. 1993;38:109–116. doi:10.1007/BF01296781
   PubMed Web of Science ®Google Scholar
• Straumann A, Spichtin HP, Bernoulli R, et al. [Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings]. Schweiz Med Wochenschr. 1994;124:1419–1429. German.
   PubMedGoogle Scholar
• Kelly KJ, Lazenby AJ, Rowe PC, et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology. 1995;109:1503–1512. doi:10.1016/0016-5085(95)90637-1
   PubMed Web of Science ®Google Scholar
• Liacouras CA, Wenner WJ, Brown K, et al. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr. 1998;26:380–385. doi:10.1097/00005176-199804000-00004
   PubMed Web of Science ®Google Scholar
• Faubion WA, Perrault J, Burgart LJ, et al. Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr. 1998;27:90–93. doi:10.1097/00005176-199807000-00016
   PubMed Web of Science ®Google Scholar
• Dellon ES, Aderoju A, Woosley JT, et al. Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. Am J Gastroenterol. 2007;102:2300–2313. doi:10.1111/j.1572-0241.2007.01396.x
   PubMed Web of Science ®Google Scholar
• Ngo P, Furuta GT, Antonioli DA, et al. Eosinophils in the esophagus–peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol. 2006;101:1666–1670. doi:10.1111/j.1572-0241.2006.00562.x
   PubMed Web of Science ®Google Scholar
• Dranove JE, Horn DS, Davis MA, et al. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr. 2009;154:96–100. doi:10.1016/j.jpeds.2008.07.042
   PubMed Web of Science ®Google Scholar
• Sayej WN, Patel R, Baker RD, et al. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2009;49:393–399. doi:10.1097/MPG.0b013e31819c4b3e
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Ferrando-Lamana L, Ripoll C, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol. 2011;9:110–117. doi:10.1016/j.cgh.2010.09.019
   PubMed Web of Science ®Google Scholar
• Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108:679–92; quiz 693. doi:10.1038/ajg.2013.71
   Web of Science ®Google Scholar
• Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128:3–20 e6; quiz 21–2. doi:10.1016/j.jaci.2011.02.040
   PubMed Web of Science ®Google Scholar
• Rodrigo S, Abboud G, Oh D, et al. High intraepithelial eosinophil counts in esophageal squamous epithelium are not specific for eosinophilic esophagitis in adults. Am J Gastroenterol. 2008;103:435–442. doi:10.1111/j.1572-0241.2007.01594.x
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Lucendo AJ. Proton pump inhibitor therapy for eosinophilic esophagitis: a paradigm shift. Am J Gastroenterol. 2017;112:1770–1773. doi:10.1038/ajg.2017.404
   PubMed Web of Science ®Google Scholar
• Wen T, Dellon ES, Moawad FJ, et al. Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. J Allergy Clin Immunol. 2015;135:187–197. doi:10.1016/j.jaci.2014.08.043
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Bredenoord AJ, Cheng E, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 2016;65:524–531. doi:10.1136/gutjnl-2015-310991
   PubMed Web of Science ®Google Scholar
• Sodikoff J, Hirano I. Proton pump inhibitor-responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis. J Allergy Clin Immunol. 2016;137:631–633. doi:10.1016/j.jaci.2015.07.008
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J. 2017;5:335–358. doi:10.1177/2050640616689525
   PubMed Web of Science ®Google Scholar
• Asher wolf W, Dellon ES. Eosinophilic esophagitis and proton pump inhibitors: controversies and implications for clinical practice. Gastroenterol Hepatol (N Y). 2014;10:427–432.
   PubMedGoogle Scholar
• Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol. 2007;102:1301–1306. doi:10.1111/j.1572-0241.2007.01179.x
   PubMed Web of Science ®Google Scholar
• Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors–inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(Suppl 1):74–81. doi:10.1046/j.1365-2036.2000.014s1074.x
   PubMed Web of Science ®Google Scholar
• Odiase E, Zhang X, Chang Y, et al. In esophageal squamous cells from eosinophilic esophagitis patients, Th2 cytokines increase eotaxin-3 secretion through effects on intracellular calcium and a non-gastric proton pump. Gastroenterology. 2021;160:2072–2088 e6. doi:10.1053/j.gastro.2021.02.016
   PubMed Web of Science ®Google Scholar
• Rochman M, Xie YM, Mack L, et al. Broad transcriptional response of the human esophageal epithelium to proton pump inhibitors. J Allergy Clin Immunol. 2021;147:1924–1935. doi:10.1016/j.jaci.2020.09.039
   PubMed Web of Science ®Google Scholar
• Zhang X, Cheng E, Huo X, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One. 2012;7:e50037. doi:10.1371/journal.pone.0050037
   PubMed Web of Science ®Google Scholar
• Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut. 2013;62:824–832. doi:10.1136/gutjnl-2012-302250
   PubMed Web of Science ®Google Scholar
• Caviglia R, Ribolsi M, Maggiano N, et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol. 2005;100:543–548. doi:10.1111/j.1572-0241.2005.40978.x
   PubMed Web of Science ®Google Scholar
• Ravelli AM, Villanacci V, Ruzzenenti N, et al. Dilated intercellular spaces: a major morphological feature of esophagitis. J Pediatr Gastroenterol Nutr. 2006;42:510–515. doi:10.1097/01.mpg.0000215312.78664.b9
   PubMed Web of Science ®Google Scholar
• Solcia E, Villani L, Luinetti O, et al. Altered intercellular glycoconjugates and dilated intercellular spaces of esophageal epithelium in reflux disease. Virchows Arch. 2000;436:207–216. doi:10.1007/s004280050032
   PubMed Web of Science ®Google Scholar
• Tobey NA, Carson JL, Alkiek RA, et al. Dilated intercellular spaces: a morphological feature of acid reflux–damaged human esophageal epithelium. Gastroenterology. 1996;111:1200–1205. doi:10.1053/gast.1996.v111.pm8898633
   PubMed Web of Science ®Google Scholar
• Villanacci V, Grigolato PG, Cestari R, et al. Dilated intercellular spaces as markers of reflux disease: histology, semiquantitative score and morphometry upon light microscopy. Digestion. 2001;64:1–8. doi:10.1159/000048833
   PubMed Web of Science ®Google Scholar
• Blanchard C, Stucke EM, Burwinkel K, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol. 2010;184:4033–4041. doi:10.4049/jimmunol.0903069
   PubMed Web of Science ®Google Scholar
• Souza RF, Huo X, Mittal V, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009;137:1776–1784. doi:10.1053/j.gastro.2009.07.055
   PubMed Web of Science ®Google Scholar
• Blevins CH, Sharma AN, Johnson ML, et al. Influence of reflux and central obesity on intercellular space diameter of esophageal squamous epithelium. United Eur Gastroenterol J. 2016;4:177–183. doi:10.1177/2050640615598426
   PubMed Web of Science ®Google Scholar
• Katzka DA, Ravi K, Geno DM, et al. Endoscopic mucosal impedance measurements correlate with eosinophilia and dilation of intercellular spaces in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015;13:1242–1248 e1. doi:10.1016/j.cgh.2014.12.032
   PubMed Web of Science ®Google Scholar
• Liu CC, Lee JW, Liu TT, et al. Relevance of ultrastructural alterations of intercellular junction morphology in inflamed human esophagus. J Neurogastroenterol Motil. 2013;19:324–331. doi:10.5056/jnm.2013.19.3.324
   PubMed Web of Science ®Google Scholar
• Orlando LA, Orlando RC. Dilated intercellular spaces as a marker of GERD. Curr Gastroenterol Rep. 2009;11:190–194. doi:10.1007/s11894-009-0030-6
   PubMedGoogle Scholar
• Vela MF, Craft BM, Sharma N, et al. Refractory heartburn: comparison of intercellular space diameter in documented GERD vs. functional heartburn. Am J Gastroenterol. 2011;106:844–850. doi:10.1038/ajg.2010.476
   PubMed Web of Science ®Google Scholar
• Neumann H, Monkemuller K, Fry LC, et al. Intercellular space volume is mainly increased in the basal layer of esophageal squamous epithelium in patients with GERD. Dig Dis Sci. 2011;56:1404–1411. doi:10.1007/s10620-010-1458-0
   PubMed Web of Science ®Google Scholar
• Calabrese C, Fabbri A, Bortolotti M, et al. Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther. 2003;18:525–532. doi:10.1046/j.1365-2036.2003.01713.x
   PubMed Web of Science ®Google Scholar
• Farre R, Blondeau K, Clement D, et al. Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique. Gut. 2011;60:885–892. doi:10.1136/gut.2010.233049
   PubMed Web of Science ®Google Scholar
• Xie C, Sifrim D, Li Y, et al. Esophageal baseline impedance reflects mucosal integrity and predicts symptomatic outcome with proton pump inhibitor treatment. J Neurogastroenterol Motil. 2018;24:43–50. doi:10.5056/jnm17032
   PubMed Web of Science ®Google Scholar
• Kessing BF, Bredenoord AJ, Weijenborg PW, et al. Esophageal acid exposure decreases intraluminal baseline impedance levels. Am J Gastroenterol. 2011;106:2093–2097. doi:10.1038/ajg.2011.276
   PubMed Web of Science ®Google Scholar
• van Rhijn BD, Weijenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014;12:1815–23 e2. doi:10.1016/j.cgh.2014.02.037
   PubMed Web of Science ®Google Scholar
• Lim LG, Neumann J, Hansen T, et al. Confocal endomicroscopy identifies loss of local barrier function in the duodenum of patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2014;20:892–900. doi:10.1097/MIB.0000000000000027
   PubMed Web of Science ®Google Scholar
• Marietta EV, Geno DM, Smyrk TC, et al. Presence of intraepithelial food antigen in patients with active eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;45:427–433. doi:10.1111/apt.13877
   PubMed Web of Science ®Google Scholar
• Ravi A, Marietta EV, Geno DM, et al. Penetration of the esophageal epithelium by dust mite antigen in patients with eosinophilic esophagitis. Gastroenterology. 2019;157:255–256. doi:10.1053/j.gastro.2019.02.042
   PubMed Web of Science ®Google Scholar
• Collins MH. Histopathologic features of eosinophilic esophagitis and eosinophilic gastrointestinal diseases. Gastroenterol Clin North Am. 2014;43:257–268. doi:10.1016/j.gtc.2014.02.007
   PubMed Web of Science ®Google Scholar
• Sherrill JD, Kc K, Wu D, et al. Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. Mucosal Immunol. 2014;7:718–729. doi:10.1038/mi.2013.90
   PubMed Web of Science ®Google Scholar
• Calabrese C, Bortolotti M, Fabbri A, et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol. 2005;100:537–542. doi:10.1111/j.1572-0241.2005.40476.x
   PubMed Web of Science ®Google Scholar
• Abdulnour-Nakhoul SM, Al-Tawil Y, Gyftopoulos AA, et al. Alterations in junctional proteins, inflammatory mediators and extracellular matrix molecules in eosinophilic esophagitis. Clin Immunol. 2013;148:265–278. doi:10.1016/j.clim.2013.05.004
   PubMed Web of Science ®Google Scholar
• Blevins CH, Iyer PG, Vela MF, et al. The esophageal epithelial barrier in health and disease. Clin Gastroenterol Hepatol. 2018;16:608–617. doi:10.1016/j.cgh.2017.06.035
   PubMed Web of Science ®Google Scholar
• Zihni C, Mills C, Matter K, et al. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol. 2016;17:564–580. doi:10.1038/nrm.2016.80
   PubMed Web of Science ®Google Scholar
• Tsukita S, Tanaka H, Tamura A. The claudins: from tight junctions to biological systems. Trends Biochem Sci. 2019;44:141–152. doi:10.1016/j.tibs.2018.09.008
   PubMed Web of Science ®Google Scholar
• Nguyen N, Fernando SD, Biette KA, et al. TGF-beta1 alters esophageal epithelial barrier function by attenuation of claudin-7 in eosinophilic esophagitis. Mucosal Immunol. 2018;11:415–426. doi:10.1038/mi.2017.72
   PubMed Web of Science ®Google Scholar
• D’Souza-Schorey C. Disassembling adherens junctions: breaking up is hard to do. Trends Cell Biol. 2005;15:19–26. doi:10.1016/j.tcb.2004.11.002
   PubMed Web of Science ®Google Scholar
• Green KJ, Jaiganesh A, Broussard JA. Desmosomes: essential contributors to an integrated intercellular junction network. F1000Res. 2019;8:2150. doi:10.12688/f1000research.20942.1
   Google Scholar
• Politi E, Angelakopoulou A, Grapsa D, et al. Filaggrin and periostin expression is altered in eosinophilic esophagitis and normalized with treatment. J Pediatr Gastroenterol Nutr. 2017;65:47–52. doi:10.1097/MPG.0000000000001419
   PubMed Web of Science ®Google Scholar
• Jovov B, Que J, Tobey NA, et al. Role of E-cadherin in the pathogenesis of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106:1039–1047. doi:10.1038/ajg.2011.102
   PubMed Web of Science ®Google Scholar
• Davis BP. Pathophysiology of eosinophilic esophagitis. Clin Rev Allergy Immunol. 2018;55:19–42. doi:10.1007/s12016-017-8665-9
   PubMed Web of Science ®Google Scholar
• Frazzoni M, Penagini R, Frazzoni L, et al. Role of reflux in the pathogenesis of eosinophilic esophagitis: comprehensive appraisal with off- and on PPI impedance-ph monitoring. Am J Gastroenterol. 2019;114:1606–1613. doi:10.14309/ajg.0000000000000379
   PubMed Web of Science ®Google Scholar
• Roan F, Obata-Ninomiya K, Ziegler SF. Epithelial cell-derived cytokines: more than just signaling the alarm. J Clin Invest. 2019;129:1441–1451. doi:10.1172/JCI124606
   PubMed Web of Science ®Google Scholar
• Afonina IS, Zhong Z, Karin M, et al. Limiting inflammation-the negative regulation of NF-kappaB and the NLRP3 inflammasome. Nat Immunol. 2017;18:861–869. doi:10.1038/ni.3772
   PubMed Web of Science ®Google Scholar
• Erger RA, Casale TB. Interleukin-8 is a potent mediator of eosinophil chemotaxis through endothelium and epithelium. Am J Physiol. 1995;268:L117–22. doi:10.1152/ajplung.1995.268.1.L117
   PubMed Web of Science ®Google Scholar
• Rot A, Krieger M, Brunner T, et al. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med. 1992;176:1489–1495. doi:10.1084/jem.176.6.1489
   PubMed Web of Science ®Google Scholar
• Fahey E, Doyle SL. IL-1 family cytokine regulation of vascular permeability and angiogenesis. Front Immunol. 2019;10:1426. doi:10.3389/fimmu.2019.01426
   PubMed Web of Science ®Google Scholar
• Persad R, Huynh HQ, Hao L, et al. Angiogenic remodeling in pediatric EoE is associated with increased levels of VEGF-A, angiogenin, IL-8, and activation of the TNF-alpha-NFkappaB pathway. J Pediatr Gastroenterol Nutr. 2012;55:251–260. doi:10.1097/MPG.0b013e31824b6391
   PubMed Web of Science ®Google Scholar
• Barthel SR, Annis DS, Mosher DF, et al. Differential engagement of modules 1 and 4 of vascular cell adhesion molecule-1 (CD106) by integrins alpha4beta1 (CD49d/29) and alphaMbeta2 (CD11b/18) of eosinophils. J Biol Chem. 2006;281:32175–32187.
   PubMed Web of Science ®Google Scholar
• Min JY, Ocampo CJ, Stevens WW, et al. Proton pump inhibitors decrease eotaxin-3/CCL26 expression in patients with chronic rhinosinusitis with nasal polyps: possible role of the nongastric H,K-ATPase. J Allergy Clin Immunol. 2017;139:130–141 e11. doi:10.1016/j.jaci.2016.07.020
   PubMed Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. doi:10.1126/science.1260419
   PubMed Web of Science ®Google Scholar
• Kewley RJ, Whitelaw ML, Chapman-Smith A. The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. Int J Biochem Cell Biol. 2004;36:189–204. doi:10.1016/S1357-2725(03)00211-5
   PubMed Web of Science ®Google Scholar
• Esser C, Rannug A, Ma Q. The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology. Pharmacol Rev. 2015;67:259–279. doi:10.1124/pr.114.009001
   PubMed Web of Science ®Google Scholar
• Fritsche E, Schafer C, Calles C, et al. Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc Natl Acad Sci U S A. 2007;104:8851–8856. doi:10.1073/pnas.0701764104
   PubMed Web of Science ®Google Scholar
• Furue M, Hashimoto-Hachiya A, Tsuji G. Antioxidative phytochemicals accelerate epidermal terminal differentiation via the AHR-OVOL1 pathway: implications for atopic dermatitis. Acta Derm Venereol. 2018;98:918–923. doi:10.2340/00015555-3003
   PubMed Web of Science ®Google Scholar
• Magiatis P, Pappas P, Gaitanis G, et al. Malassezia yeasts produce a collection of exceptionally potent activators of the Ah (dioxin) receptor detected in diseased human skin. J Invest Dermatol. 2013;133:2023–2030. doi:10.1038/jid.2013.92
   PubMed Web of Science ®Google Scholar
• Takei K, Mitoma C, Hashimoto-Hachiya A, et al. Antioxidant soybean tar Glyteer rescues T-helper-mediated downregulation of filaggrin expression via aryl hydrocarbon receptor. J Dermatol. 2015;42:171–180. doi:10.1111/1346-8138.12717
   PubMed Web of Science ®Google Scholar
• Furue M, Tsuji G, Mitoma C, et al. Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor. J Dermatol Sci. 2015;80:83–88. doi:10.1016/j.jdermsci.2015.07.011
   PubMed Web of Science ®Google Scholar
• Tsuji G, Hashimoto-Hachiya A, Kiyomatsu-Oda M, et al. Aryl hydrocarbon receptor activation restores filaggrin expression via OVOL1 in atopic dermatitis. Cell Death Dis. 2017;8:e2931. doi:10.1038/cddis.2017.322
   PubMed Web of Science ®Google Scholar
• van den Bogaard EH, Podolsky MA, Smits JP, et al. Genetic and pharmacological analysis identifies a physiological role for the AHR in epidermal differentiation. J Invest Dermatol. 2015;135:1320–1328. doi:10.1038/jid.2015.6
   PubMed Web of Science ®Google Scholar
• van den Bogaard EH, Bergboer JG, Vonk-Bergers M, et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest. 2013;123:917–927. doi:10.1172/JCI65642
   PubMed Web of Science ®Google Scholar
• Rothhammer V, Quintana FJ. The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. Nat Rev Immunol. 2019;19:184–197. doi:10.1038/s41577-019-0125-8
   PubMed Web of Science ®Google Scholar
• Barroso A, Mahler JV, Fonseca-Castro PH, et al. The aryl hydrocarbon receptor and the gut–brain axis. Cell Mol Immunol. 2021;18(2):259–268. doi:10.1038/s41423-020-00585-5
   PubMed Web of Science ®Google Scholar
• Quattrochi LC, Tukey RH. Nuclear uptake of the Ah (dioxin) receptor in response to omeprazole: transcriptional activation of the human CYP1A1 gene. Mol Pharmacol. 1993;43:504–508.
   PubMed Web of Science ®Google Scholar
• Curi-Pedrosa R, Daujat M, Pichard L, et al. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther. 1994;269:384–392.
   PubMed Web of Science ®Google Scholar
• Hu W, Sorrentino C, Denison MS, et al. Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol. 2007;71:1475–1486. doi:10.1124/mol.106.032748
   PubMed Web of Science ®Google Scholar
• Vinit C, Dieme A, Courbage S, et al. Eosinophilic esophagitis: pathophysiology, diagnosis, and management. Arch Pediatr. 2019;26:182–190. doi:10.1016/j.arcped.2019.02.005
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Rivas MD, Hernandez-Alonso M, et al. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. Aliment Pharmacol Ther. 2014;40:955–965. doi:10.1111/apt.12914
   PubMed Web of Science ®Google Scholar
• Park JY, Zhang X, Nguyen N, et al. Proton pump inhibitors decrease eotaxin-3 expression in the proximal esophagus of children with esophageal eosinophilia. PLoS One. 2014;9:e101391. doi:10.1371/journal.pone.0101391
   PubMed Web of Science ®Google Scholar
• Iwakura N, Fujiwara Y, Tanaka F, et al. Basophil infiltration in eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia. Aliment Pharmacol Ther. 2015;41:776–784. doi:10.1111/apt.13141
   PubMed Web of Science ®Google Scholar
• Bolton SM, Kagalwalla AF, Arva NC, et al. Mast cell infiltration is associated with persistent symptoms and endoscopic abnormalities despite resolution of eosinophilia in pediatric eosinophilic esophagitis. Am J Gastroenterol. 2020;115:224–233. doi:10.14309/ajg.0000000000000474
   PubMed Web of Science ®Google Scholar
• Kanagaratham C, El Ansari YS, Sallis BF, et al. Omeprazole inhibits IgE-mediated mast cell activation and allergic inflammation induced by ingested allergen in mice. J Allergy Clin Immunol. 2020;146:884–893 e5. doi:10.1016/j.jaci.2020.02.032
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:13–22 e1. doi:10.1016/j.cgh.2015.07.041
   PubMed Web of Science ®Google Scholar
• Peterson KA, Thomas KL, Hilden K, et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci. 2010;55:1313–1319. doi:10.1007/s10620-009-0859-4
   PubMed Web of Science ®Google Scholar
• Moawad FJ, Veerappan GR, Dias JA, et al. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol. 2013;108:366–372. doi:10.1038/ajg.2012.443
   PubMed Web of Science ®Google Scholar
• Mangla S, Goldin AH, Singal G, et al. Endoscopic features and eosinophil density are associated with food impaction in adults with esophageal eosinophilia. Dig Dis Sci. 2016;61:2578–2584. doi:10.1007/s10620-016-4190-6
   PubMed Web of Science ®Google Scholar
• Dellon ES, Speck O, Woodward K, et al. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. Am J Gastroenterol. 2013;108:1854–1860. doi:10.1038/ajg.2013.363
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Sugawa T, Tanaka F, et al. A multicenter study on the prevalence of eosinophilic esophagitis and PPI-responsive esophageal eosinophilic infiltration. Intern Med. 2012;51:3235–3239. doi:10.2169/internalmedicine.51.8670
   PubMed Web of Science ®Google Scholar
• Francis DL, Foxx-Orenstein A, Arora AS, et al. Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2012;35:300–307. doi:10.1111/j.1365-2036.2011.04922.x
   PubMed Web of Science ®Google Scholar
• Vazquez-Elizondo G, Ngamruengphong S, Khrisna M, et al. The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. Aliment Pharmacol Ther. 2013;38:1312–1319. doi:10.1111/apt.12513
   PubMed Web of Science ®Google Scholar
• Martinek A, Spicak J, Spicak J, Spicak J, Spicak J. Treatment with proton pump inhibitors is effective in a majority of adults patients with eosinophilic esophagitis. Gastroenterology. 2013;144:S493. doi:10.1016/S0016-5085(13)61823-5
   Google Scholar
• Gomez-Torrijos E, Garcia-Rodriguez R, Castro-Jimenez A, et al. The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia. Aliment Pharmacol Ther. 2016;43:534–540. doi:10.1111/apt.13496
   PubMed Web of Science ®Google Scholar
• Philpott H, Nandurkar S, Royce SG, et al. A prospective open clinical trial of a proton pump inhibitor, elimination diet and/or budesonide for eosinophilic oesophagitis. Aliment Pharmacol Ther. 2016;43:985–993. doi:10.1111/apt.13576
   PubMed Web of Science ®Google Scholar
• DiGiovanni EL, Champeaux AL, Arroyo MR, et al. Esophageal eosinophilia treated with long-duration proton pump inhibitor therapy. ACG Case Rep J. 2016;3:95–97. doi:10.14309/crj.2016.11
   PubMedGoogle Scholar
• Potter JW, Saeian K, Staff D, et al. Eosinophilic esophagitis in adults: an emerging problem with unique esophageal features. Gastrointest Endosc. 2004;59:355–361. doi:10.1016/S0016-5107(03)02713-5
   PubMed Web of Science ®Google Scholar
• Nantes Castillejo O, Zozaya JM, Jimenez-Perez FJ, et al. [Incidence and characteristics of eosinophilic esophagitis in adults]. An Sist Sanit Navar. 2009;32:227–234. Spanish. doi:10.23938/ASSN.0161
   PubMed Web of Science ®Google Scholar
• Garrean CP, Zhang Q, Gonsalves N, et al. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy. Am J Gastroenterol. 2008;103:1631–1637. doi:10.1111/j.1572-0241.2008.01829.x
   PubMed Web of Science ®Google Scholar
• Jung YM, Lee HS, Lee DH, et al. [Clinical significance of incidentally detected eosinophilic esophagitis with pathologic review]. Korean J Gastroenterol. 2010;55:162–168. Korean. doi:10.4166/kjg.2010.55.3.162
   PubMedGoogle Scholar
• Abe Y, Iijima K, Ohara S, et al. A Japanese case series of 12 patients with esophageal eosinophilia. J Gastroenterol. 2011;46:25–30. doi:10.1007/s00535-010-0295-4
   PubMed Web of Science ®Google Scholar
• Levy AN, Rahaman SM, Bonis PA, et al. Hiccups as a presenting symptom of eosinophilic esophagitis. Case Rep Gastroenterol. 2012;6:340–343. doi:10.1159/000338739
   PubMedGoogle Scholar
• Tomomatsu Y, Yoshino J, Inui K, et al. Clinical features of eosinophilic esophagitis: ten Japanese cases. Dig Endosc. 2013;25:117–124. doi:10.1111/j.1443-1661.2012.01340.x
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim MJ, Kim JH, et al. Clinical analysis of primary eosinophilic esophagitis. J Neurogastroenterol Motil. 2013;19:204–209. doi:10.5056/jnm.2013.19.2.204
   PubMed Web of Science ®Google Scholar
• Lipka S, Muhammad A, Champeaux A, et al. Case report of proton pump inhibitor responsive esophageal eosinophilia: why 2 months of proton pump inhibitors is required. Dis Esophagus. 2016;29:700–703. doi:10.1111/dote.12237
   PubMed Web of Science ®Google Scholar
• Ahn B, Lee DH, Lee CM, et al. [Proton pump inhibitor-responsive esophageal eosinophilia: an overview of cases from One University Hospital Center]. Korean J Gastroenterol. 2016;67:178–182. Korean. doi:10.4166/kjg.2016.67.4.178
   PubMedGoogle Scholar
• Frazzoni M, Frazzoni L, De Bortoli N, et al. Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance-pH parameters implying anti-reflux mechanism of action. Aliment Pharmacol Ther. 2021;53:1183–1189. doi:10.1111/apt.16371
   PubMed Web of Science ®Google Scholar
• Peterson KA, Yoshigi M, Hazel MW, et al. RNA sequencing confirms similarities between PPI-responsive oesophageal eosinophilia and eosinophilic oesophagitis. Aliment Pharmacol Ther. 2018;48:219–225. doi:10.1111/apt.14825
   PubMed Web of Science ®Google Scholar
• Laserna-Mendieta EJ, Casabona S, Guagnozzi D, et al. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. Aliment Pharmacol Ther. 2020;52:798–807. doi:10.1111/apt.15957
   PubMed Web of Science ®Google Scholar
• Eke R, Li T, White A, et al. Systematic review of histological remission criteria in eosinophilic esophagitis. JGH Open. 2018;2:158–165. doi:10.1002/jgh3.12059
   PubMed Web of Science ®Google Scholar
• McElhiney J, Lohse MR, Arora AS, et al. The Mayo Dysphagia Questionnaire-30: documentation of reliability and validity of a tool for interventional trials in adults with esophageal disease. Dysphagia. 2010;25:221–230. doi:10.1007/s00455-009-9246-8
   PubMed Web of Science ®Google Scholar
• Laserna-Mendieta EJ, FitzGerald JA, Arias-Gonzalez L, et al. Esophageal microbiome in active eosinophilic esophagitis and changes induced by different therapies. Sci Rep. 2021;11:7113. doi:10.1038/s41598-021-86464-z
   PubMed Web of Science ®Google Scholar
• Rank MA, Sharaf RN, Furuta GT, et al. Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters. Gastroenterology. 2020;158:1789–1810 e15. doi:10.1053/j.gastro.2020.02.039
   PubMed Web of Science ®Google Scholar
• Sultan S, Falck-Ytter Y, Inadomi JM. The AGA institute process for developing clinical practice guidelines part one: grading the evidence. Clin Gastroenterol Hepatol. 2013;11:329–332. doi:10.1016/j.cgh.2013.02.001
   PubMed Web of Science ®Google Scholar
• Reed CC, Wolf WA, Cotton CC, et al. Optimal histologic cutpoints for treatment response in patients with eosinophilic esophagitis: analysis of data from a prospective cohort study. Clin Gastroenterol Hepatol. 2018;16:226–233 e2. doi:10.1016/j.cgh.2017.09.046
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Rodriguez-Sanchez J, Martinek J, et al. Long-term loss of response in proton pump inhibitor-responsive esophageal eosinophilia is uncommon and influenced by CYP2C19 genotype and rhinoconjunctivitis. Am J Gastroenterol. 2015;110:1567–1575. doi:10.1038/ajg.2015.314
   PubMed Web of Science ®Google Scholar
• Thakkar M, Keene S, Dellon ES, Dellon ES. Long-term outcomes and durability of response of proton pump inhibitor treatment in eosinophilic esophagitis. Gastroenterology. 2021;160:S-256:S-257. doi:10.1016/S0016-5085(21)01351-2
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. 2019 Prescribed Medicines. Medical Expenditure Panel Survey (MEPS). Rockville, MD: Agency for Healthcare Research and Quality; 2021.
   Google Scholar
• Business Wire. Global Proton Pump Inhibitors Market to Surpass US$ 3.5 Billion by 2027, Says Coherent Market Insights (CMI). Seattle, WA: Business Wire; 2020.
   Google Scholar
• Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115–1127. doi:10.1053/j.gastro.2010.08.023
   PubMed Web of Science ®Google Scholar
• Brisebois S, Merati A, Giliberto JP. Proton pump inhibitors: review of reported risks and controversies. Laryngoscope Investig Otolaryngol. 2018;3:457–462. doi:10.1002/lio2.187
   PubMed Web of Science ®Google Scholar
• De Bruyne P, Ito S. Toxicity of long-term use of proton pump inhibitors in children. Arch Dis Child. 2018;103:78–82. doi:10.1136/archdischild-2017-314026
   PubMed Web of Science ®Google Scholar
• Administration USFaD. FDA drug safety communication: Clostridium difficile associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). 2012.
   Google Scholar
• Administration USFaD. FDA drug safety communication: possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. 2011.
   Google Scholar
• Administration USFaD. FDA drug safety communication: low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs), 2011.
   Google Scholar
• Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63:552–558. doi:10.1136/gutjnl-2013-304738
   PubMed Web of Science ®Google Scholar
• Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5:337–344. doi:10.1586/ecp.12.20
   PubMed Web of Science ®Google Scholar
• Nguyen PA, Islam M, Galvin CJ, et al. Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. Int J Qual Health Care. 2020;32:292–299. doi:10.1093/intqhc/mzaa041
   PubMed Web of Science ®Google Scholar
• Wang CH, Li CH, Hsieh R, et al. Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized controlled trials and observational studies. Expert Opin Drug Saf. 2019;18:163–172. doi:10.1080/14740338.2019.1577820
   PubMed Web of Science ®Google Scholar
• Xun X, Yin Q, Fu Y, et al. Proton pump inhibitors and the risk of community-acquired pneumonia: an updated meta-analysis. Ann Pharmacother. 2021;10600280211039240. doi:10.1177/10600280211039240
   Web of Science ®Google Scholar
• Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34:1269–1281. doi:10.1111/j.1365-2036.2011.04874.x
   PubMed Web of Science ®Google Scholar
• Hafiz RA, Wong C, Paynter S, et al. The risk of community-acquired enteric infection in proton pump inhibitor therapy: systematic review and meta-analysis. Ann Pharmacother. 2018;52:613–622. doi:10.1177/1060028018760569
   PubMed Web of Science ®Google Scholar
• Vilcu AM, Sabatte L, Blanchon T, et al. Association between acute gastroenteritis and continuous use of proton pump inhibitors during winter periods of highest circulation of enteric viruses. JAMA Netw Open. 2019;2:e1916205. doi:10.1001/jamanetworkopen.2019.16205
   PubMed Web of Science ®Google Scholar
• Cheung KS, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Therap Adv Gastroenterol. 2019;12:1756284819834511. doi:10.1177/1756284819834511
   Web of Science ®Google Scholar
• Li Z, Wu C, Li L, et al. Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: a meta-analysis. Saudi J Gastroenterol. 2017;23:222–228. doi:10.4103/sjg.SJG_573_16
   PubMed Web of Science ®Google Scholar
• Abbas MK, Zaidi ARZ, Robert CA, et al. The safety of long-term daily usage of a proton pump inhibitor: a literature review. Cureus. 2019;11:e5563. doi:10.7759/cureus.5563
   PubMed Web of Science ®Google Scholar
• Vengrus CS, Delfino VD, Bignardi PR. Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease: systematic review and meta-analysis. Minerva Urol Nephrol. 2021;73. doi:10.23736/S2724-6051.21.04116-3
   PubMed Web of Science ®Google Scholar
• Wijarnpreecha K, Thongprayoon C, Chesdachai S, et al. Associations of proton-pump inhibitors and h2 receptor antagonists with chronic kidney disease: a meta-analysis. Dig Dis Sci. 2017;62:2821–2827. doi:10.1007/s10620-017-4725-5
   PubMed Web of Science ®Google Scholar
• Hussain S, Singh A, Habib A, et al. Proton pump inhibitors use and risk of chronic kidney disease: evidence-based meta-analysis of observational studies. Clin Epidemiol Glob Health. 2019;7:46–52. doi:10.1016/j.cegh.2017.12.008
   Web of Science ®Google Scholar
• Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33:331–342. doi:10.1093/ndt/gfw470
   PubMed Web of Science ®Google Scholar
• Cheema E. Investigating the association of proton pump inhibitors with chronic kidney disease and its impact on clinical practice and future research: a review. J Pharm Policy Pract. 2019;12:6. doi:10.1186/s40545-019-0167-0
   PubMedGoogle Scholar
• Peng CC, Tu YK, Lee GY, et al. Effects of proton pump inhibitors on glycemic control and incident diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2021;106:3354–3366. doi:10.1210/clinem/dgab353
   PubMed Web of Science ®Google Scholar
• Sanchez-Garcia A, Simental-Mendia M, Simental-Mendia LE. Effect of proton-pump inhibitors on glucose and insulin metabolism on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Curr Pharm Des. 2020;26:4007–4013. doi:10.2174/1381612826666200523170718
   PubMed Web of Science ®Google Scholar
• Janetzki JL, Sykes MJ, Ward MB, et al. Proton pump inhibitors may contribute to progression or development of chronic obstructive pulmonary disease-a sequence symmetry analysis approach. J Clin Pharm Ther. 2021;46:1687–1694. doi:10.1111/jcpt.13520
   PubMed Web of Science ®Google Scholar
• Kikuchi S, Imai H, Tani Y, et al. Proton pump inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2020;8:CD013113. doi:10.1002/14651858.CD013113.pub2
   PubMedGoogle Scholar
• Desai M, Nutalapati V, Srinivasan S, et al. Proton pump inhibitors do not increase the risk of dementia: a systematic review and meta-analysis of prospective studies. Dis Esophagus. 2020;33. doi:10.1093/dote/doaa041
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liang M, Sun C, et al. Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies. Eur J Clin Pharmacol. 2020;76:139–147. doi:10.1007/s00228-019-02753-7
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhan J, Bao Q, et al. Possible dementia risk of proton pump inhibitors and H2 receptor blockers use in the treatment of Helicobacter pylori: a meta-analysis study. Med Hypotheses. 2020;144:109989. doi:10.1016/j.mehy.2020.109989
   PubMed Web of Science ®Google Scholar
• Wijarnpreecha K, Thongprayoon C, Panjawatanan P, et al. Proton pump inhibitors and risk of dementia. Ann Transl Med. 2016;4:240. doi:10.21037/atm.2016.06.14
   PubMed Web of Science ®Google Scholar
• Song YQ, Li Y, Zhang SL, et al. Proton pump inhibitor use does not increase dementia and Alzheimer’s disease risk: an updated meta-analysis of published studies involving 642305 patients. PLoS One. 2019;14:e0219213. doi:10.1371/journal.pone.0219213
   PubMed Web of Science ®Google Scholar
• Khan MA, Yuan Y, Iqbal U, et al. No association linking short-term proton pump inhibitor use to dementia: systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2020;115:671–678. doi:10.14309/ajg.0000000000000500
   PubMed Web of Science ®Google Scholar
• Huang B, Huang Y, Li Y, et al. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch Med Res. 2012;43:212–224. doi:10.1016/j.arcmed.2012.04.004
   PubMed Web of Science ®Google Scholar
• Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2017;22:142–152. doi:10.1177/1074248416663647
   PubMed Web of Science ®Google Scholar
• Hu W, Tong J, Kuang X, et al. Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: a meta-analysis. Medicine (Baltimore). 2018;97:e9638. doi:10.1097/MD.0000000000009638
   PubMed Web of Science ®Google Scholar
• Sun S, Cui Z, Zhou M, et al. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis. Neurogastroenterol Motil. 2017;29:e12926. doi:10.1111/nmo.12926
   Web of Science ®Google Scholar
• Sherwood MW, Melloni C, Jones WS, et al. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4. doi:10.1161/JAHA.115.002245
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Dormuth CR, Huang A, et al. Proton pump inhibitors and the risk of adverse cardiac events. PLoS One. 2013;8:e84890. doi:10.1371/journal.pone.0084890
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:682–691 e2. doi:10.1053/j.gastro.2019.05.056
   PubMed Web of Science ®Google Scholar
• Maggio M, Corsonello A, Ceda GP, et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013;173:518–523. doi:10.1001/jamainternmed.2013.2851
   PubMed Web of Science ®Google Scholar
• Xie Y, Bowe B, Yan Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019;365:l1580. doi:10.1136/bmj.l1580
   PubMed Web of Science ®Google Scholar
• Ben-Eltriki M, Green CJ, Maclure M, et al. Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence. Pharmacol Res Perspect. 2020;8:e00651. doi:10.1002/prp2.651
   PubMed Web of Science ®Google Scholar
• Brown JP, Tazare JR, Williamson E, et al. Proton pump inhibitors and risk of all-cause and cause-specific mortality: a cohort study. Br J Clin Pharmacol. 2021;87:3150–3161. doi:10.1111/bcp.14728
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706–715. doi:10.1053/j.gastro.2017.01.031
   PubMed Web of Science ®Google Scholar
• Jena AB, Sun E, Goldman DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med. 2013;28:223–230. doi:10.1007/s11606-012-2211-5
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Abrams JA. Does confounding explain the association between PPIs and Clostridium difficile-related diarrhea? Am J Gastroenterol. 2013;108:278–279. doi:10.1038/ajg.2012.395
   PubMed Web of Science ®Google Scholar
• Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther. 2021;109:1417–1423. doi:10.1002/cpt.2015
   PubMed Web of Science ®Google Scholar
• Schroeder S, Capocelli KE, Masterson JC, et al. Effect of proton pump inhibitor on esophageal eosinophilia. J Pediatr Gastroenterol Nutr. 2013;56:166–172. doi:10.1097/MPG.0b013e3182716b7a
   PubMed Web of Science ®Google Scholar
• Rea F, Caldaro T, Tambucci R, et al. Eosinophilic esophagitis: is it also a surgical disease? J Pediatr Surg. 2013;48:304–308. doi:10.1016/j.jpedsurg.2012.11.006
   PubMed Web of Science ®Google Scholar
• Gutierrez-Junquera C, Fernandez-Fernandez S, Cilleruelo ML, et al. High prevalence of response to proton-pump inhibitor treatment in children with esophageal eosinophilia. J Pediatr Gastroenterol Nutr. 2016;62:704–710. doi:10.1097/MPG.0000000000001019
   PubMed Web of Science ®Google Scholar
• Gomez Torrijos E, Donado Palencia P, Sanchez Miranda MP, et al. Eosinophilic esophagitis: treatment with different doses of omeprazole in children under 16 years. J Investig Allergol Clin Immunol. 2018;28:191–192. doi:10.18176/jiaci.0230
   PubMed Web of Science ®Google Scholar
• Vieira GG, Ribeiro LBM, Truppel SK, et al. Endoscopic and histological characteristics in patients with eosinophilic esophagitis responsive and non-responsive to proton pump inhibitors. J Pediatr (Rio J). 2020;96:638–643. doi:10.1016/j.jped.2019.05.005
   PubMed Web of Science ®Google Scholar
• Dohil R, Newbury RO, Aceves S. Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis. Dig Dis Sci. 2012;57:1413–1419. doi:10.1007/s10620-011-1991-5
   PubMed Web of Science ®Google Scholar
• Gutierrez-Junquera C, Fernandez-Fernandez S, Cilleruelo ML, et al. Long-term treatment with proton pump inhibitors is effective in children with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2018;67:210–216. doi:10.1097/MPG.0000000000001952
   PubMed Web of Science ®Google Scholar
• Schmidt E, Peiper U. [Influence of initial stretch on the dynamics of vascular smooth muscle]. Pflugers Arch. 1972;333:314–325. German. doi:10.1007/BF00586211
   PubMed Web of Science ®Google Scholar
• Barron JJ, Tan H, Spalding J, et al. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr. 2007;45:421–427. doi:10.1097/MPG.0b013e31812e0149
   PubMed Web of Science ®Google Scholar
• Blank ML, Parkin L. National study of off-label proton pump inhibitor use among New Zealand Infants in the first year of life (2005–2012). J Pediatr Gastroenterol Nutr. 2017;65:179–184. doi:10.1097/MPG.0000000000001596
   PubMed Web of Science ®Google Scholar
• El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14:447–460. doi:10.1080/17425255.2018.1461835
   PubMed Web of Science ®Google Scholar
• Kuhn BR, Young AJ, Justice AE, et al. Infant acid suppression use is associated with the development of eosinophilic esophagitis. Dis Esophagus. 2020;33. doi:10.1093/dote/doaa073
   PubMed Web of Science ®Google Scholar
• Jensen ET, Kuhl JT, Martin LJ, et al. Prenatal, intrapartum, and postnatal factors are associated with pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2018;141:214–222. doi:10.1016/j.jaci.2017.05.018
   PubMed Web of Science ®Google Scholar
• Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117:e817–20. doi:10.1542/peds.2005-1655
   PubMed Web of Science ®Google Scholar
• Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:516–554. doi:10.1097/MPG.0000000000001889
   PubMed Web of Science ®Google Scholar
• Rosh JR, Hassall E. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. J Pediatr Gastroenterol Nutr. 2006;43:545. doi:10.1097/01.mpg.0000239994.20270.a8
   PubMedGoogle Scholar
• Lima JJ, Lang JE, Mougey EB, et al. Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. J Pediatr. 2013;163:686–691. doi:10.1016/j.jpeds.2013.03.017
   PubMed Web of Science ®Google Scholar
• Wechsler JB, Hirano I. Biological therapies for eosinophilic gastrointestinal diseases. J Allergy Clin Immunol. 2018;142:24–31 e2. doi:10.1016/j.jaci.2018.05.018
   PubMed Web of Science ®Google Scholar
• Ko E, Chehade M. Biological therapies for eosinophilic esophagitis: where do we stand? Clin Rev Allergy Immunol. 2018;55:205–216. doi:10.1007/s12016-018-8674-3
   PubMed Web of Science ®Google Scholar
• Huang C, Chen L, Savage SR, et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021;39:361–379 e16. doi:10.1016/j.ccell.2020.12.007
   PubMed Web of Science ®Google Scholar
• Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019;105:1095–1105. doi:10.1002/cpt.1304
   PubMed Web of Science ®Google Scholar
• Shoda T, Wen T, Aceves SS, et al. Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. Lancet Gastroenterol Hepatol. 2018;3:477–488. doi:10.1016/S2468-1253(18)30096-7
   PubMed Web of Science ®Google Scholar
• Canas JA, Tabares A, Barbero C, et al. Proton-pump inhibitor response prediction using esophageal microRNAs in children with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2020;71:755–763. doi:10.1097/MPG.0000000000002957
   PubMed Web of Science ®Google Scholar
• Cicali EJ, Blake K, Gong Y, et al. Novel implementation of genotype-guided proton pump inhibitor medication therapy in children: a pilot, randomized, multisite pragmatic trial. Clin Transl Sci. 2019;12:172–179. doi:10.1111/cts.12589
   PubMed Web of Science ®Google Scholar
• Jensen ET, Dellon ES. Environmental factors and eosinophilic esophagitis. J Allergy Clin Immunol. 2018;142:32–40. doi:10.1016/j.jaci.2018.04.015
   PubMed Web of Science ®Google Scholar
• Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1–48. doi:10.18637/jss.v036.i03
   Web of Science ®Google Scholar
• Garrean CP, Patil D, Gonsalves N, et al. S1860 comparison of endoscopic and histologic response in patients with eosinophilic esophagitis treated with proton pump inhibition, topical fluticasone, and dietary elimination. Gastroenterology. 2009;136:A–279. doi:10.1016/S0016-5085(09)61275-0
   Web of Science ®Google Scholar
• Mangla S, Singal G, Hornick JL, et al. Su1866 clinical predictors of response to proton pump inhibitors in patients with esophageal eosinophilia. Gastroenterology. 2013;144:S-495–S-496. doi:10.1016/S0016-5085(13)61831-4
   Web of Science ®Google Scholar
• Harris BR, Hon E, Gupta SK. Implementation of guidelines in eosinophilic esophagitis at an academic pediatric practice. Dis Esophagus. 2018;31. doi:10.1093/dote/doy029
   PubMed Web of Science ®Google Scholar
• Rosen I, Mahamed A, Garah J, et al. The management and course of eosinophilic oesophagitis in Israeli children. Acta Paediatr. 2021;110:1653–1657. doi:10.1111/apa.15746
   PubMed Web of Science ®Google Scholar
• Shoda T, Matsuda A, Nomura I, et al. Eosinophilic esophagitis versus proton pump inhibitor-responsive esophageal eosinophilia: transcriptome analysis. J Allergy Clin Immunol. 2017;139:2010–2013 e4. doi:10.1016/j.jaci.2016.11.028
   PubMed Web of Science ®Google Scholar
• Moawad FJ, Wells JM, Johnson RL, et al. Comparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2015;42:231–238. doi:10.1111/apt.13258
   PubMed Web of Science ®Google Scholar
• Votto M, De Filippo M, Castagnoli R, et al. Non-invasive biomarkers of eosinophilic esophagitis. Acta Biomed. 2021;92:e2021530. doi:10.23750/abm.v92iS7.12401
   PubMedGoogle Scholar